First cancer virotherapy medicine
RIGVIR® contains a live nonpathogenic ECHO-7 virus that has not been genetically modified. RIGVIR® is oncotropic and oncolytic. It finds and selectively infects tumour cells, a process called oncotropism. Then, RIGVIR® replicates in tumour cells and destroys them, a process called oncolysis.
Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment, which improves time to progression, survival and quality of life of cancer patients. RIGVIR® is well tolerated and does not cause serious adverse events. The most common side effect is subfebrile temperature for 1-3 days. This is reversible and does not need to be treated.
RIGVIR® is the first oncolytic virus in the world, which is registered for cancer virotherapy and introduced in medical practice. RIGVIR® was approved in Latvia in 2004 for cutaneous melanoma therapy. Since 2011 RIGVIR® is fully reimbursed for residents of Latvia and from 2015 included in the guidelines for skin cancer and melanoma treatment. Since 2015 RIGVIR® is approved in Georgia and since 2016 it is approved in Armenia.